Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 113
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 24
The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment
Angelica Varesi, Lucrezia Irene Maria Campagnoli, Foroogh Fahmideh, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12289-12289
Open Access | Times Cited: 46
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases
Elizabeth M. Rhea, Alice Babin, P. C. Thomas, et al.
Tissue Barriers (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 27
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Why to Study Peptides from Venomous and Poisonous Animals?
Ana Oliveira, Andreimar M. Soares, Saulo L. da Silva
International Journal of Peptide Research and Therapeutics (2023) Vol. 29, Iss. 5
Open Access | Times Cited: 13
Role of mitogen-activated protein kinase inhibitors in Alzheimer's disease: Rouge of brain kinases
Suad Hamdan Almasoudi, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Brain Research Bulletin (2025) Vol. 224, pp. 111296-111296
Open Access
Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy
Xiaoyan Yang, Peng Feng, Hongxu Zhu, et al.
View (2025)
Open Access
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Dong-Jun Lv, Peng Feng, Xueying Guan, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders
Junchen Si, Kai Yu, Jiheng Hao, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhidong Zhou, Ling Yi, Karolina Popławska-Domaszewicz, et al.
Pharmacological Research (2025) Vol. 216, pp. 107770-107770
Open Access
A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease
Zijuan Zhang, Ming Shi, Zhengmin Li, et al.
Parkinson s Disease (2023) Vol. 2023, pp. 1-13
Open Access | Times Cited: 9
Antidiabetic drugs in Parkinson’s disease
Yoshajandith Aguirre-Vidal, Sergio Montes, Ana Carolina Mota-López, et al.
Clinical Parkinsonism & Related Disorders (2024) Vol. 11, pp. 100265-100265
Open Access | Times Cited: 3
DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model
Lingyu Zhang, Chun Li, Zijuan Zhang, et al.
Parkinson s Disease (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 13
Targeting Autophagy: A Promising Therapeutic Strategy for Diabetes Mellitus and Diabetic Nephropathy
Qirui Li, Huiying Xu, Rui-Ting Ma, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 10, pp. 2153-2182
Open Access | Times Cited: 2
Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
David Vogrinc, Sara Redenšek, Tanja Blagus, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e39157-e39157
Open Access | Times Cited: 2
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson’s Disease
Jace Jones-Tabah
Journal of Molecular Biology (2022) Vol. 435, Iss. 12, pp. 167927-167927
Open Access | Times Cited: 11
A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres
Zejing Gao, Yi Wei, Guanghui Ma
Journal of Materials Chemistry B (2023) Vol. 11, Iss. 47, pp. 11184-11197
Closed Access | Times Cited: 6
Network Pharmacology and Molecular Docking Analyses Unveil the Mechanisms of Yiguanjian Decoction against Parkinson’s Disease from Inner/Outer Brain Perspective
Zhongqi Shen, Meng Yu, Shaozhi Zhang
BioMed Research International (2022) Vol. 2022, pp. 1-25
Open Access | Times Cited: 9
Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
Yazhou Li, Kelli L. Vaughan, Yun Wang, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4397-4414
Open Access | Times Cited: 1
Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders
Corneliu Toader, Călin Petru Tătaru, Octavian Munteanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13614-13614
Open Access | Times Cited: 1
Metallic Nanocarriers for Therapeutic Peptides: Emerging Solutions Addressing the Delivery Challenges in Brain Ailments
Shanmuga Sharan Rathnam, Thirumalai Deepak, Badri Narayana Sahoo, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 388, Iss. 1, pp. 39-53
Open Access | Times Cited: 3
Metabolic reprogramming of the inflammatory response in the nervous system: the crossover between inflammation and metabolism
Jesús Amo‐Aparicio, Charles A. Dinarello, Rubèn López‐Vales
Neural Regeneration Research (2023) Vol. 19, Iss. 10, pp. 2189-2201
Open Access | Times Cited: 3
Functional engineering of human iPSC‐derived parasympathetic neurons enhances responsiveness to gastrointestinal hormones
Yuka Akagi, Yuzo Takayama, Yuma Nihashi, et al.
FEBS Open Bio (2023) Vol. 14, Iss. 1, pp. 63-78
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top